Stoke Therapeutics Inc (NASDAQ:STOK)
| 18.12 Delayed Data As of Jan 21 |  -0.02 / -0.11%Today’s Change | 17.71 Today|||52-Week Range 69.52 | -24.47% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Biotechnology | MARKET CAP $720.0M |
Company Description
Stoke Therapeutics, Inc. is a biotechnology company, which engages in the research and development of treatments for genetic diseases. It offers a wide range of relevant tissues including the central nervous system, eye, kidney, and liver. The company was founded by Isabel Aznarez and Adrian R. Krainer in June 2014 and is headquartered in Bedford, MA.
Contact Information
Stoke Therapeutics, Inc. 45 Wiggins Avenue Bedford Massachusetts 01730 |
Employees
Shareholders
| Individual stakeholders | 97.13% |
| Other institutional | 30.75% |
| Mutual fund holders | 21.74% |
Top Executives
| Edward M. Kaye | Chief Executive Officer & Director |
| Huw M. Nash | Chief Operating & Business Officer |
| Stephen J. Tulipano | Chief Financial Officer |
| Barry S. Ticho | Chief Medical Officer |
| Gene Liau | Chief Scientific Officer |
